Abstract:Introduction: The Local Lymph Node Assay (LLNA) has been designated as the first-choice in vivo assay for identification the skin sensitization potential of new chemicals. The LLNA:BrdU-ELISA is a validated non-radioactive modification to the LLNA. An intra-laboratory reproducibility study for the LLNA: BrdU-ELISA was conducted to demonstrate its adequate performance in our laboratory.Methods: Ten independent LLNA: BrdU-ELISAs with the preferred positive controls (PCs), i.e., 25% hexyl cinnamic aldehyde (HCA) and 25% eugenol, were conducted within a period of less than one year. In addition, different concentrations of 2,4-dinitrochlorobenzene (DNCB, an extreme sensitizer) (0.01, 0.1 and 0.3%), HCA (10, 25 and 50%) and eugenol (10, 25 and 50%), were tested to determine the EC1.6 values. Special Pathogen Free female CBA/J mice of 8-10weeks old were randomly allocated to the groups, each group having 4mice. 25 mu l of AOO (vehicle, acetone: olive oil = 4: 1, v/v) or HCA, eugenol, DNCB at the needed concentration was applied to the dorsum of each ear of the mice, daily for 3 consecutive days. A single intraperitoneal injection of 0.5 ml of BrdU solution (10 mg/ml) was given on day 5. On day 6, a pair of auricular lymph nodes from each mouse was excised, and BrdU ELISA analysis was conducted.Results: The result for each group is expressed as the mean Stimulation Index (SI). The mean of the 10 mean SIs for 25% HCA (2.58 +/- 0.95) and 25% eugenol (3.51 +/- 1.25) was not significantly different to that from the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) (i.e., the data on the formal validation study for the LLNA: BrdU-ELISA by the ICCVAM) (3.03 +/- 2.00 for 25% HCA, 6.13 +/- 6.06 for 25% eugenol) (P > 0.05), with even smaller Coefficient of Variations (CV) (36.8% for 25% HCA, 35.6% for 25% eugenol) than that from the ICCVAM (66.0% for 25% HCA, 98.8% for 25% eugenol). In addition, the EC1.6 values for HCA, eugenol and DNCB (15.2, 12.5 and 0.25%, respectively) were consistent with that from the ICCVAM (12.92, 8.85 and 0.34%, respectively).Discussion: The results indicate that the reliability for our laboratory to conduct the LLNA: BrdU-ELISA is successfully determined. (C) 2016 Elsevier Inc. All rights reserved.

The within‐ and between‐laboratory reproducibility and predictive capacity of the in chemico amino acid derivative reactivity assay: Results of validation study implemented in four participating laboratories

Amino acid derivative reactivity assay–organic solvent reaction system: A novel alternative test for skin sensitization capable of assessing highly hydrophobic substances

The underlying factors that explain why nucleophilic reagents rarely co-elute with test chemicals in the ADRA

Oxidation of a cysteine-derived nucleophilic reagent by dimethyl sulfoxide in the amino acid derivative reactivity assay

Borderline Range Determined Using Data From Validation Study of Alternative Methods for Skin Sensitization: ADRA, IL‐8 Luc Assay, and EpiSensA

Development of an in chemico high-throughput screening method for the identification of skin sensitization potential

Improved performance of the SH test as an in vitro skin sensitization test with a new predictive model and decision tree

Increasing Accessibility of Bayesian Network-Based Defined Approaches for Skin Sensitisation Potency Assessment

Validation of the GARD™skin Assay for Assessment of Chemical Skin Sensitizers: Ring Trial Results of Predictive Performance and Reproducibility

GARDskin dose-response assay and its application in conducting Quantitative Risk Assessment (QRA) for fragrance materials using a Next Generation Risk Assessment (NGRA) framework

Skin Sensitization Potency Prediction Based on Read‐Across (RAx) Incorporating RhE‐Based Testing Strategy (RTSv1)–Defined Approach: RTSv1‐Based RAx

Integrated skin sensitization assessment based on OECD methods (II): Hazard and potency by combining kinetic peptide reactivity and the "2 out of 3" Defined Approach

Proteomic allergen-peptide/protein interaction assay for the identification of human skin sensitizers

Predicting points of departure and potency categories for fragrance ingredients by integrating OECD in vitro models

Validation study of a new reconstructed human epidermis model EPiTRI for in vitro skin irritation test according to OECD guidelines

Intra-laboratory Study to Determine the Reproducibility of LLNA:BrdU-ELISA for the Prediction of the Skin Sensitizing Potential of Chemicals.

Skin Sensitisation Case Study: Comparison of Defined Approaches including OECD 497 Guidance

Development of a peptide reactivity assay for screening botanicals and natural substances: Proof of concept studies

Quantitative evaluation of adalimumab and anti-adalimumab antibodies in sera using a surface plasmon resonance biosensor

Computational application of internationally harmonized defined approaches to skin sensitization: DASS App

Validation of a method for the determination of Aderamastat (FP-025) in K2EDTA human plasma by LC-MS/MS